Julian D Gillmore

List of Publications by Year
in descending order

153 papers	13,700 citations	28274 55 h-index	22832 112 g-index
158 all docs	158 docs citations	158 times ranked	7678 citing authors

#	Article	IF	Citations
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine, 2021, 385, 493-502.	27.0	807
3	Systemic amyloidosis. Lancet, The, 2016, 387, 2641-2654.	13.7	703
4	Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. New England Journal of Medicine, 2002, 346, 1786-1791.	27.0	621
5	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 2015, 132, 1570-1579.	1.6	442
6	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
7	A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018, 39, 2799-2806.	2.2	396
8	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 2013, 121, 3420-3427.	1.4	385
9	Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165.	5.3	339
10	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 2015, 126, 612-615.	1.4	334
11	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
12	T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251.	2.2	310
13	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. New England Journal of Medicine, 2015, 373, 1106-1114.	27.0	304
14	Magnetic Resonance in TransthyretinÂCardiac Amyloidosis. Journal of the American College of Cardiology, 2017, 70, 466-477.	2.8	290
15	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation, 2019, 140, 16-26.	1.6	288
16	Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome. Journal of the American Heart Association, 2013, 2, e000098.	3.7	275
17	CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 133-142.	5.3	242
18	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230

#	Article	IF	Citations
19	Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations. Human Mutation, 2014, 35, E2403-E2412.	2.5	220
20	Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	210
21	Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. European Heart Journal Cardiovascular Imaging, 2014, 15, 1289-1298.	1.2	184
22	Native T1 and Extracellular Volume inÂTransthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 810-819.	5.3	172
23	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
24	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology, 2015, 277, 388-397.	7.3	146
25	Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen AÎ±-Chain Amyloidosis. Journal of the American Society of Nephrology: JASN, 2009, 20, 444-451.	6.1	145
26	Myocardial Edema and Prognosis inÂAmyloidosis. Journal of the American College of Cardiology, 2018, 71, 2919-2931.	2.8	145
27	Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. European Heart Journal, 2017, 38, 1905-1908.	2.2	144
28	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	5.3	136
29	A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood, 2019, 134, 2271-2280.	1.4	130
30	A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. European Heart Journal, 2015, 36, 1098-1105.	2.2	129
31	Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. European Heart Journal Cardiovascular Imaging, 2017, 18, 1344-1350.	1.2	124
32	Guidelines on the diagnosis and investigation of AL amyloidosis. British Journal of Haematology, 2015, 168, 207-218.	2.5	122
33	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica, 2014, 99, 1479-1485.	3.5	118
34	Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 2006, 107, 1227-1229.	1.4	113
35	Cardiac Structural and Functional Consequences of Amyloid Deposition byÂCardiac Magnetic Resonance andÂEchocardiography and TheirÂPrognosticÂRoles. JACC: Cardiovascular Imaging, 2019, 12, 823-833.	5.3	113
36	Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC: Cardiovascular Imaging, 2021, 14, 189-199.	5.3	113

#	Article	IF	Citations
37	A novel mechanoâ€enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Molecular Medicine, 2015, 7, 1337-1349.	6.9	109
38	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447.	2.2	108
39	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
40	Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology, 2010, 148, 760-767.	2.5	106
41	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematology,the, 2015, 2, e241-e250.	4.6	105
42	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97
43	A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. Journal of Clinical Pathology, 2015, 68, 314-317.	2.0	95
44	Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Science Translational Medicine, 2018, 10, .	12.4	94
45	Pathophysiology and treatment of systemic amyloidosis. Nature Reviews Nephrology, 2013, 9, 574-586.	9.6	93
46	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	10.2	93
47	Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1539-1544.	7.1	91
48	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. British Journal of Haematology, 2006, 134, 417-425.	2.5	84
49	Structure, Folding Dynamics, and Amyloidogenesis of D76N Î²2-Microglobulin. Journal of Biological Chemistry, 2013, 288, 30917-30930.	3.4	80
50	High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematology,the, 2019, 6, e217-e228.	4.6	80
51	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
52	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological Chemistry, 2018, 293, 14192-14199.	3.4	68
53	RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667.	13.7	64
54	Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. Immunology, 2004, 112, 255-264.	4.4	63

#	Article	IF	Citations
55	Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 162-166.	3.0	61
56	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin Mâ€“Related Light Chain Amyloidosis. Journal of Clinical Oncology, 2016, 34, 2037-2045.	1.6	60
57	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy, 2020, 34, 357-370.	2.6	55
58	Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residueâ€”a case series and genetic exploration. Rheumatology, 2017, 56, 209-213.	1.9	49
59	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48
60	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 153-162.	3.0	47
61	Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. European Heart Journal, 2022, 43, 333-341.	2.2	45
62	Quantitation of ^{99m}Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 203-210.	3.0	42
63	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
64	Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurology and Therapy, 2021, 10, 375-389.	3.2	34
65	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	2.1	34
66	Drug Insight: emerging therapies for amyloidosis. Nature Clinical Practice Nephrology, 2006, 2, 263-270.	2.0	33
67	The transthyretin amyloidoses: advances in therapy. Postgraduate Medical Journal, 2015, 91, 439-448.	1.8	33
68	Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. American Journal of Transplantation, 2022, 22, 1646-1657.	4.7	30
69	Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Human Mutation, 2019, 40, 90-96.	2.5	29
70	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. Scientific Reports, 2019, 9, 1388.	3.3	27
71	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632.	2.2	27
72	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2021, 22, 1304-1311.	1.2	26

#	Article	IF	Citations
73	ALchemy - A Large Prospective â€˜Real World' Study of Chemotherapy in AL Amyloidosis. Blood, 2011, 118, 992-992.	1.4	26
74	Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2022, 24, 1700-1712.	7.1	26
75	Renal Amyloidosis Associated With 5 NovelÂVariants in the Fibrinogen A Alpha Chain Protein. Kidney International Reports, 2017, 2, 461-469.	0.8	25
76	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. Blood, 2010, 116, 988-988.	1.4	25
77	Two types of amyloid in a single heart. Blood, 2014, 124, 3025-3027.	1.4	24
78	Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 8-13.	3.0	24
79	Systemic embolism in amyloid transthyretin cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1387-1396.	7.1	23
80	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure, 2020, 7, 3942-3949.	3.1	22
81	Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre. Clinical Chemistry and Laboratory Medicine, 2020, 58, 948-957.	2.3	20
82	Cardiac Magnetic Resonanceâ€“Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. Circulation: Cardiovascular Imaging, 2021, 14, CIRCIMAGING121012506.	2.6	19
83	Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrology Dialysis Transplantation, 2016, 33, gfw375.	0.7	18
84	Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 189-193.	3.0	17
85	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16
86	Cardiac Amyloidosis: A Review of Current Imaging Techniques. Frontiers in Cardiovascular Medicine, 2021, 8, 751293.	2.4	16
87	Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. Haematologica, 2014, 99, e260-e263.	3.5	14
88	A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype. European Journal of Medical Genetics, 2016, 59, 474-477.	1.3	14
89	Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. Journal of Proteomics, 2017, 165, 113-118.	2.4	14
90	Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis â€“ Results From the UK Amyloidosis Treatment Trial.. Blood, 2009, 114, 2869-2869.	1.4	13

#	Article	IF	Citations
91	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. Nature Communications, 2021, 12, 7112.	12.8	13
92	Imaging-Guided Treatment for Cardiac Amyloidosis. Current Cardiology Reports, 2022, 24, 839-850.	2.9	13
93	001â€...Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. Heart, 2017, 103, A1-A2.	2.9	12
94	Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. Journal of Biological Chemistry, 2020, 295, 11379-11387.	3.4	12
95	A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 189-198.	3.0	12
96	Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies. Journal of Clinical Pathology, 2014, 67, 661-666.	2.0	11
97	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet Journal of Rare Diseases, 2021, 16, 204.	2.7	11
98	Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. Blood, 2006, 108, 129-129.	1.4	11
99	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 2022, 9, 830006.	3.5	11
100	Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK. Advances in Therapy, 2022, 39, 2292-2301.	2.9	11
101	The value of screening biopsies in lightâ€chain (AL) and transthyretin (ATTR) amyloidosis. European Journal of Haematology, 2020, 105, 352-356.	2.2	10
102	A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid. BMC Medical Imaging, 2017, 17, 3.	2.7	9
103	Amyloid cardiomyopathy associated with a novel apolipoprotein Aâ€"I Q172P variant. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 252-253.	3.0	8
104	Comparison of Free Light Chain Assays. American Journal of Clinical Pathology, 2016, 146, 78-85.	0.7	8
105	Misidentification of transthyretin and immunoglobulin variants by proteomics due to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 229-237.	3.0	8
106	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart, 2022, 108, 474-478.	2.9	8
107	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	1.7	8
108	The role of serial ^{99m}Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 38-49.	3.0	8

#	Article	IF	Citations
109	Extracellular volume with bolusâ€only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time. Journal of Magnetic Resonance Imaging, 2018, 47, 1677-1684.	3.4	7
110	Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. Cardiology Clinics, 2021, 39, 389-402.	2.2	7
111	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. Blood, 2008, 112, 1689-1689.	1.4	7
112	Two types of systemic amyloidosis in a single patient. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 275-276.	3.0	6
113	Lysozyme amyloid: evidence for the W64R variant by proteomics in the absence of the wild type protein. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 206-207.	3.0	6
114	Karyomegalic interstitial nephritis with a novel FAN1 gene mutation and concurrent ALECT2 amyloidosis. BMC Nephrology, 2020, 21, 74.	1.8	6
115	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. Blood, 2008, 112, 869-869.	1.4	6
116	A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.. Blood, 2009, 114, 2796-2796.	1.4	6
117	In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. Blood, 2009, 114, 745-745.	1.4	6
118	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. Sleep Medicine, 2017, 32, 191-197.	1.6	5
119	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres. Molecules, 2021, 26, 1913.	3.8	5
120	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. Blood, 2011, 118, 995-995.	1.4	5
121	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	1.4	5
122	Response to Letters Regarding Article, â€œPrognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosisâ€. Circulation, 2016, 133, e450-1.	1.6	4
123	Six-minute walk test (6MWT) in AL amyloidosis â€“ baseline and 12-month follow-up after chemotherapy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 62-63.	3.0	4
124	Clinical ApoAâ€IV amyloid is associated with fibrillogenic signal sequence. Journal of Pathology, 2021, 255, 311-318.	4.5	4
125	Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment.. Blood, 2009, 114, 1791-1791.	1.4	4
126	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 72-73.	3.0	3

#	Article	IF	Citations
127	028â€…Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping. Heart, 2017, 103, A24-A24.	2.9	3
128	Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 52-53.	3.0	3
129	The UK National Amyloidosis Centre. European Heart Journal, 2019, 40, 1661-1664.	2.2	3
130	Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin lightâ€chain (AL) amyloidosis. British Journal of Haematology, 2021, 194, 1016-1023.	2.5	3
131	Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. Blood, 2008, 112, 1733-1733.	1.4	3
132	Incidence and predictors of worsening heart failure in patients with wildâ€type transthyretin cardiac amyloidosis. ESC Heart Failure, 2022, 9, 2978-2987.	3.1	3
133	Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. Blood, 2005, 106, 3495-3495.	1.4	2
134	A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.. Blood, 2012, 120, 2966-2966.	1.4	2
135	The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis. Blood, 2020, 136, 16-17.	1.4	2
136	When to Suspect and How to Approach a Diagnosis of Amyloidosis. American Journal of Medicine, 2022, 135, S2-S8.	1.5	2
137	Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis. Blood, 2014, 124, 726-726.	1.4	1
138	Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,. Blood, 2011, 118, 3975-3975.	1.4	1
139	Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,. Blood, 2011, 118, 3978-3978.	1.4	1
140	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. Blood, 2012, 120, 4074-4074.	1.4	1
141	Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD). Blood, 2014, 124, 1198-1198.	1.4	1
142	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. Blood, 2020, 136, 40-40.	1.4	1
143	024â€…Spectrum and significance of CMR findings in cardiac transthyretin amyloidosis. Heart, 2017, 103, A20-A21.	2.9	0
144	3â€…Treatment response in cardiac al amyloidosis assessed by CMR: findings at 3 months, 6 months and 1 year post-chemotherapy. , 2018, , .		0

#	Article	IF	Citations
145	AB0901â€…TWO TYPES OF SYSTEMIC AMYLOIDOSIS IN A SINGLE PATIENT. , 2019, , .		0
146	19â€…Myocardial perfusion mapping in cardiac amyloidosis- unearthing the spectrum from infiltration to ischaemia. , 2019, , .		0
147	21â€…Intracardiac thrombi in cardiac amyloidosis, a common finding. , 2019, , .		0
148	Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis. Neurology: Clinical Practice, 2021, 11, e757-e759.	1.6	0
149	Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.. Blood, 2009, 114, 2814-2814.	1.4	0
150	Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.. Blood, 2009, 114, 1863-1863.	1.4	0
151	Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases. Blood, 2010, 116, 3958-3958.	1.4	0
152	A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis. Blood, 2014, 124, 305-305.	1.4	0
153	The UK Experience of Renal Transplantation in AL Amyloidosis. Blood, 2019, 134, 2206-2206.	1.4	0